Functional Assays to Screen and Dissect Genomic Hits
Authors:
- Kiran MusunuruKMKiran Musunuru
- Daniel BernsteinDBDaniel Bernstein
- F. Sessions ColeFCF. Sessions Cole
- Mustafa K. KhokhaMKMustafa K. Khokha
- Frank S. LeeFLFrank S. Lee
- Shin LinSLShin Lin
- Thomas V. McDonaldTMThomas V. McDonald
- Ivan P. MoskowitzIMIvan P. Moskowitz
- Thomas QuertermousTQThomas Quertermous
- Vijay G. SankaranVSVijay G. Sankaran
- David A. SchwartzDSDavid A. Schwartz
- Edwin K. SilvermanESEdwin K. Silverman
- 1 April 2018
- journal article
- review article
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 11 (4) , e002178
Abstract
The National Institutes of Health have made substantial investments in genomic studies and technologies to identify DNA sequence variants associated with human disease phenotypes. The National Heart, Lung, and Blood Institute has been at the forefront of these commitments to ascertain genetic variation associated with heart, lung, blood, and sleep diseases and related clinical traits. Genome-wide association studies, exome- and genome-sequencing studies, and exome-genotyping studies of the National Heart, Lung, and Blood Institute–funded epidemiological and clinical case–control studies are identifying large numbers of genetic variants associated with heart, lung, blood, and sleep phenotypes. However, investigators face challenges in identification of genomic variants that are functionally disruptive among the myriad of computationally implicated variants. Studies to define mechanisms of genetic disruption encoded by computationally identified genomic variants require reproducible, adaptable, and inexpensive methods to screen candidate variant and gene function. High-throughput strategies will permit a tiered variant discovery and genetic mechanism approach that begins with rapid functional screening of a large number of computationally implicated variants and genes for discovery of those that merit mechanistic investigation. As such, improved variant-to-gene and gene-to-function screens—and adequate support for such studies—are critical to accelerating the translation of genomic findings. In this White Paper, we outline the variety of novel technologies, assays, and model systems that are making such screens faster, cheaper, and more accurate, referencing published work and ongoing work supported by the National Heart, Lung, and Blood Institute’s R21/R33 Functional Assays to Screen Genomic Hits program. We discuss priorities that can accelerate the impressive but incomplete progress represented by big data genomic research.Keywords
This publication has 72 references indexed in Scilit:
- The 4D nucleome projectNature, 2017
- An Interspecies Heart-to-Heart: Using Xenopus to Uncover the Genetic Basis of Congenital Heart DiseaseCurrent Pathobiology Reports, 2017
- Congenital Heart Disease Genetics Uncovers Context-Dependent Organization and Function of Nucleoporins at CiliaDevelopmental Cell, 2016
- A Chronic Obstructive Pulmonary Disease Susceptibility Gene, FAM13A , Regulates Protein Stability of β-CateninAmerican Journal of Respiratory and Critical Care Medicine, 2016
- Integrative approaches for large-scale transcriptome-wide association studiesNature Genetics, 2016
- Integrative analysis of 111 reference human epigenomesNature, 2015
- Human high-altitude adaptation: forward genetics meets the HIF pathwayGenes & Development, 2014
- Disease-Related Growth Factor and Embryonic Signaling Pathways Modulate an Enhancer of TCF21 Expression at the 6q23.2 Coronary Heart Disease LocusPLOS Genetics, 2013
- Enhanced Efficiency of Human Pluripotent Stem Cell Genome Editing through Replacing TALENs with CRISPRsCell Stem Cell, 2013
- Systematic dissection and optimization of inducible enhancers in human cells using a massively parallel reporter assayNature Biotechnology, 2012